Preliminary Results of INT230-6 Study Show Promising Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INTS?
Source: Newsfilter
- Significant Efficacy: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the standard of care group, indicating the potential advantage of INT230-6.
- Improved Safety: There was a 44% reduction in grade 3 or higher adverse events in patients receiving INT230-6 compared to the standard treatment group, suggesting a significant safety advantage that could enhance patient treatment experiences.
- Enrollment Progress: The company has submitted a protocol amendment to Swissmedic to resume patient enrollment, planning to optimize the treatment regimen by lowering the drug volume ratio, with an expected total enrollment of up to 61 patients to further validate efficacy.
- Market Potential: Given that pCR is a key indicator for FDA accelerated approval, the success of INT230-6 could provide the company with faster market access opportunities, particularly in treating difficult-to-manage triple-negative breast cancer, which holds significant strategic importance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.720
Low
1.50
Averages
3.33
High
5.00
Current: 7.720
Low
1.50
Averages
3.33
High
5.00
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensity Therapeutics Updates on INVINCIBLE-4 Study Progress
- Study Progress Update: Intensity Therapeutics submitted a protocol amendment in March 2026 to resume enrollment in the INVINCIBLE-4 study using a lower drug volume ratio, with an expected total enrollment of 61 patients, demonstrating the company's ongoing commitment to the research.
- Safety Observations: As of March 2, 2026, safety data for patients receiving INT230-6 combined with standard treatment show favorable outcomes, with a significant 44% reduction in grade 3 or higher adverse events compared to standard treatment alone, providing a positive outlook for future clinical applications.
- Preliminary pCR Data: Fourteen patients have been treated to date, and while pCR analysis is ongoing, initial results suggest that the use of INT230-6 may enhance the pathological complete response rate, which holds potential clinical significance, especially in triple-negative breast cancer patients.
- Market Potential Assessment: With approximately 56,000 new cases of triple-negative breast cancer diagnosed annually in the U.S., the development of INT230-6 may offer a new treatment option for this high-risk group, aligning with FDA accelerated approval standards and presenting significant market opportunities.
See More
Preliminary Results of INT230-6 Study Show Promising Efficacy
- Significant Efficacy: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the standard of care group, indicating the potential advantage of INT230-6.
- Improved Safety: There was a 44% reduction in grade 3 or higher adverse events in patients receiving INT230-6 compared to the standard treatment group, suggesting a significant safety advantage that could enhance patient treatment experiences.
- Enrollment Progress: The company has submitted a protocol amendment to Swissmedic to resume patient enrollment, planning to optimize the treatment regimen by lowering the drug volume ratio, with an expected total enrollment of up to 61 patients to further validate efficacy.
- Market Potential: Given that pCR is a key indicator for FDA accelerated approval, the success of INT230-6 could provide the company with faster market access opportunities, particularly in treating difficult-to-manage triple-negative breast cancer, which holds significant strategic importance.
See More
Intensity Therapeutics Regains Nasdaq Compliance
- Compliance Notification: Intensity Therapeutics has received a notice from Nasdaq confirming that the company has regained compliance with the minimum bid price requirement of $1.00 per share, indicating a recognition of the company's stability in the capital markets.
- Stock Performance: For the last 10 consecutive business days, from February 19, 2026, to March 4, 2026, the closing bid price of the company's common stock was at or above $1.00, demonstrating a gradual restoration of market confidence in the company's stock.
- Market Reaction: In premarket trading, INTS shares rose by 0.9% to $7.79, reflecting a positive investor response to the compliance restoration, which may stimulate future investment interest.
- Strategic Implications: Regaining compliance not only enhances the company's image among investors but also potentially provides greater flexibility for future financing and business expansion, thereby strengthening the company's competitive position in the market.
See More
Intensity Therapeutics Regains Nasdaq Compliance
- Nasdaq Compliance Restored: Intensity Therapeutics has received formal notice from Nasdaq confirming compliance with Listing Rule 5550(a)(2), as the company's stock price remained above $1.00 for 10 consecutive business days from February 19 to March 4, 2026, enhancing its market stability.
- Clinical Trial Progress: The company has completed two clinical studies with over 200 patients enrolled in trials for INT230-6, including a Phase 1/2 dose escalation study for metastatic cancers and a Phase 2 randomized controlled trial for locally advanced breast cancer, demonstrating significant potential in cancer treatment.
- New Drug Development Outlook: INT230-6, the company's lead investigational product, utilizes the proprietary DfuseRx℠ technology platform for direct intratumoral injection, effectively killing tumor cells and activating the immune system, which could shift the treatment paradigm for malignancies resistant to conventional immunotherapy.
- Future Development Plans: The company has initiated a Phase 3 trial for soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group, aiming to evaluate the combined effects of INT230-6 with standard immunochemotherapy, further advancing its strategic positioning in cancer treatment.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Impact: Intensity Therapeutics announced a 1-for-25 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq listing requirements, reducing outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help regain compliance with Nasdaq's minimum bid price.
- Weak Stock Performance: Despite broader market gains, with the S&P 500 up 0.24%, the company's stock plummeted 26.70% to $0.27, nearing its 52-week low of $0.18, indicating that company-specific factors are adversely affecting its performance.
- Technical Analysis Signals: The stock is currently trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day simple moving average, indicating significant short-term weakness; however, with an RSI of 46.41 in neutral territory and a MACD above its signal line, there are mixed momentum signals.
- Future Earnings Outlook: The upcoming earnings report on March 12, 2026, is anticipated to be a major catalyst, with an EPS estimate of a loss of 5 cents, an improvement from a loss of 22 cents year-over-year, although revenue is projected at zero, highlighting ongoing challenges in profitability.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Intensity Therapeutics has announced a 1-for-25 reverse stock split approved by its board and shareholders, aimed at boosting the per-share price to meet Nasdaq's minimum listing requirements, set to take effect on February 18, consolidating every 25 existing shares into one.
- Trading Change Details: Following the reverse split, Intensity Therapeutics stock will begin trading on February 19 under the new CUSIP number 45828J 202 while retaining the ticker symbol INTS, which will alter the share structure for investors.
- Market Reaction: Following the announcement, Intensity Therapeutics stock traded nearly 30% lower in Friday's premarket, indicating a negative market reaction to the company's price adjustment, which may affect investor confidence.
- Compliance Pressure: This reverse stock split reflects the compliance pressures faced by the company, as failure to meet Nasdaq's listing standards could lead to delisting, thereby impacting the company's ability to raise capital and its market image.
See More
Intensity Therapeutics Updates on INVINCIBLE-4 Study Progress
- Study Progress Update: Intensity Therapeutics submitted a protocol amendment in March 2026 to resume enrollment in the INVINCIBLE-4 study using a lower drug volume ratio, with an expected total enrollment of 61 patients, demonstrating the company's ongoing commitment to the research.
- Safety Observations: As of March 2, 2026, safety data for patients receiving INT230-6 combined with standard treatment show favorable outcomes, with a significant 44% reduction in grade 3 or higher adverse events compared to standard treatment alone, providing a positive outlook for future clinical applications.
- Preliminary pCR Data: Fourteen patients have been treated to date, and while pCR analysis is ongoing, initial results suggest that the use of INT230-6 may enhance the pathological complete response rate, which holds potential clinical significance, especially in triple-negative breast cancer patients.
- Market Potential Assessment: With approximately 56,000 new cases of triple-negative breast cancer diagnosed annually in the U.S., the development of INT230-6 may offer a new treatment option for this high-risk group, aligning with FDA accelerated approval standards and presenting significant market opportunities.
See More
Preliminary Results of INT230-6 Study Show Promising Efficacy
- Significant Efficacy: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the standard of care group, indicating the potential advantage of INT230-6.
- Improved Safety: There was a 44% reduction in grade 3 or higher adverse events in patients receiving INT230-6 compared to the standard treatment group, suggesting a significant safety advantage that could enhance patient treatment experiences.
- Enrollment Progress: The company has submitted a protocol amendment to Swissmedic to resume patient enrollment, planning to optimize the treatment regimen by lowering the drug volume ratio, with an expected total enrollment of up to 61 patients to further validate efficacy.
- Market Potential: Given that pCR is a key indicator for FDA accelerated approval, the success of INT230-6 could provide the company with faster market access opportunities, particularly in treating difficult-to-manage triple-negative breast cancer, which holds significant strategic importance.
See More
Intensity Therapeutics Regains Nasdaq Compliance
- Compliance Notification: Intensity Therapeutics has received a notice from Nasdaq confirming that the company has regained compliance with the minimum bid price requirement of $1.00 per share, indicating a recognition of the company's stability in the capital markets.
- Stock Performance: For the last 10 consecutive business days, from February 19, 2026, to March 4, 2026, the closing bid price of the company's common stock was at or above $1.00, demonstrating a gradual restoration of market confidence in the company's stock.
- Market Reaction: In premarket trading, INTS shares rose by 0.9% to $7.79, reflecting a positive investor response to the compliance restoration, which may stimulate future investment interest.
- Strategic Implications: Regaining compliance not only enhances the company's image among investors but also potentially provides greater flexibility for future financing and business expansion, thereby strengthening the company's competitive position in the market.
See More
Intensity Therapeutics Regains Nasdaq Compliance
- Nasdaq Compliance Restored: Intensity Therapeutics has received formal notice from Nasdaq confirming compliance with Listing Rule 5550(a)(2), as the company's stock price remained above $1.00 for 10 consecutive business days from February 19 to March 4, 2026, enhancing its market stability.
- Clinical Trial Progress: The company has completed two clinical studies with over 200 patients enrolled in trials for INT230-6, including a Phase 1/2 dose escalation study for metastatic cancers and a Phase 2 randomized controlled trial for locally advanced breast cancer, demonstrating significant potential in cancer treatment.
- New Drug Development Outlook: INT230-6, the company's lead investigational product, utilizes the proprietary DfuseRx℠ technology platform for direct intratumoral injection, effectively killing tumor cells and activating the immune system, which could shift the treatment paradigm for malignancies resistant to conventional immunotherapy.
- Future Development Plans: The company has initiated a Phase 3 trial for soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group, aiming to evaluate the combined effects of INT230-6 with standard immunochemotherapy, further advancing its strategic positioning in cancer treatment.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Impact: Intensity Therapeutics announced a 1-for-25 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq listing requirements, reducing outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help regain compliance with Nasdaq's minimum bid price.
- Weak Stock Performance: Despite broader market gains, with the S&P 500 up 0.24%, the company's stock plummeted 26.70% to $0.27, nearing its 52-week low of $0.18, indicating that company-specific factors are adversely affecting its performance.
- Technical Analysis Signals: The stock is currently trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day simple moving average, indicating significant short-term weakness; however, with an RSI of 46.41 in neutral territory and a MACD above its signal line, there are mixed momentum signals.
- Future Earnings Outlook: The upcoming earnings report on March 12, 2026, is anticipated to be a major catalyst, with an EPS estimate of a loss of 5 cents, an improvement from a loss of 22 cents year-over-year, although revenue is projected at zero, highlighting ongoing challenges in profitability.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Intensity Therapeutics has announced a 1-for-25 reverse stock split approved by its board and shareholders, aimed at boosting the per-share price to meet Nasdaq's minimum listing requirements, set to take effect on February 18, consolidating every 25 existing shares into one.
- Trading Change Details: Following the reverse split, Intensity Therapeutics stock will begin trading on February 19 under the new CUSIP number 45828J 202 while retaining the ticker symbol INTS, which will alter the share structure for investors.
- Market Reaction: Following the announcement, Intensity Therapeutics stock traded nearly 30% lower in Friday's premarket, indicating a negative market reaction to the company's price adjustment, which may affect investor confidence.
- Compliance Pressure: This reverse stock split reflects the compliance pressures faced by the company, as failure to meet Nasdaq's listing standards could lead to delisting, thereby impacting the company's ability to raise capital and its market image.
See More
